Brought to you by 
Genzyme gets rights to Osiris's Prochymal and Chondrogen; deal terminated
07 Jan 2016
Executive Summary
In a deal potentially worth $1.38bn in up-fronts and total milestones, Genzyme received exclusive rights to develop and commercialize stem cell company Osiris Therapeutics' Prochymal and Chondrogen adult stem cell products worldwide, with the exception of the US and Canada, where Osiris retains rights; and in Japan, where Prochymal was previously licensed in the graft-versus-host disease (GvHD) indication.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Gene Therapy, Cell Therapy
Deal Status
- Terminated
Deal Type
-
Alliance
- Includes Royalty or Profit Split Information
- Intra-Biotech Deal
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Genzyme gets rights to Osiris's Prochymal and Chondrogen; deal terminated
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice